Angiosoma Stock Today
| GSTC Stock | USD 0.0003 0.00 0.00% |
Performance1 of 100
| Odds Of DistressOver 66
|
AngioSoma is trading at 3.0E-4 as of the 12th of December 2024, a No Change since the beginning of the trading day. The stock's open price was 3.0E-4. AngioSoma has more than 66 % chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 12th of November 2024 and ending today, the 12th of December 2024. Click here to learn more.
GlobeStar Therapeutics Corporation, a clinical stage pharmaceutical company, focuses on developing a patented formulation of drugs for the treatment of multiple sclerosis and other neurodegenerative diseases. The company was incorporated in 2016 and is based in Richland, Washington. The company has 770.36 M outstanding shares. More on AngioSoma
Moving against AngioSoma Pink Sheet
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
AngioSoma Pink Sheet Highlights
| Business Concentration | null, null, Biotechnology, Healthcare (View all Sectors) |
AngioSoma [GSTC] is a Pink Sheet which is traded through a dealer network over-the-counter (OTC). The company currently falls under 'Nano-Cap' category with a current market capitalization of 8.47 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate AngioSoma's market, we take the total number of its shares issued and multiply it by AngioSoma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. AngioSoma conducts business under null sector and is part of null industry. The entity has 770.36 M outstanding shares.
AngioSoma currently holds about 12 in cash with (327 K) of positive cash flow from operations.
Check AngioSoma Probability Of Bankruptcy
Ownership AllocationAngioSoma holds a total of 770.36 Million outstanding shares. AngioSoma shows 10.02 percent of its outstanding shares held by insiders and 0.02 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check AngioSoma Ownership Details
AngioSoma Risk Profiles
| Mean Deviation | 10.88 | |||
| Semi Deviation | 12.71 | |||
| Standard Deviation | 17.21 | |||
| Variance | 296.33 |
AngioSoma Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in AngioSoma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Volatility Analysis Now
Volatility AnalysisGet historical volatility and risk analysis based on latest market data |
| All Next | Launch Module |
AngioSoma Corporate Management
| Robert CPA | Treasurer CFO | Profile | |
| Brooke Greenwald | Chief Officer | Profile | |
| James Katzaroff | CEO and President | Profile | |
| Steven Penderghast | Commercial Director | Profile | |
| David Croom | Ex VP | Profile | |
| William BSc | Dev Director | Profile |
Other Information on Investing in AngioSoma Pink Sheet
AngioSoma financial ratios help investors to determine whether AngioSoma Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in AngioSoma with respect to the benefits of owning AngioSoma security.